STRIvE-02: A First-in-Human Phase I Study of Systemically Administered B7-H3 Chimeric Antigen Receptor T Cells for Patients With Relapsed/Refractory Solid Tumors
B7-H3 CAR T cells are tolerable and demonstrate limited antitumor activity without acute on-target, off-tumor toxicity. High levels of CAR T cell expansion may be necessary to achieve objective responses, but undefined host and tumor microenvironment factors appear to be critical (ClinicalTrials.gov identifier: NCT04483778).
Authors
- Safia Cheeney
- Michael C. Jensen (ORCID: https://orcid.org/0000-0001-7477-3063)
- Sowmya Pattabhi (ORCID: https://orcid.org/0000-0003-4403-0925)
- Julie R. Park (ORCID: https://orcid.org/0000-0002-6777-9165)
- Rimas J. Orentas (ORCID: https://orcid.org/0000-0002-6310-3467)
- Joshua A. Gustafson (ORCID: https://orcid.org/0000-0002-0735-7235)
- Ashley Wilson (ORCID: https://orcid.org/0000-0002-4440-001X)
- Heather Herd Gustafson (ORCID: https://orcid.org/0000-0002-5484-5821)
- Katelyn Burleigh (ORCID: https://orcid.org/0000-0003-2832-2071)
- Nicholas A. Vitanza (ORCID: https://orcid.org/0000-0002-3966-4985)
- Catherine M. Albert (ORCID: https://orcid.org/0000-0001-7610-9932)
- Stephanie Rawlings-Rhea
- Christopher Brown (ORCID: https://orcid.org/0000-0003-0834-4003)
- Wenjun Huang (ORCID: https://orcid.org/0000-0001-8948-7262)
- Jason Wendler (ORCID: https://orcid.org/0000-0003-4195-8138)
- Rebecca Gardner (ORCID: https://orcid.org/0000-0003-1532-3200)
- Navin Pinto (ORCID: https://orcid.org/0000-0002-8775-6710)
- Kristy Seidel (ORCID: https://orcid.org/0000-0002-8402-0900)
- Mallory Taylor (ORCID: https://orcid.org/0000-0002-8998-4530)
- Heidi B. Ullom
Institutions
- Seattle Children's Hospital (US)
- University of Washington (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2024-09-10
- DOI
- https://doi.org/10.1200/jco.23.02229
- Citations
- 33
- Primary Topic
- CAR-T cell therapy research
- Type
- article
- Field-Weighted Citation Impact
- 9.32